The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino) benzoyl]-2, 3, 4, 5-tetrahydro-1H-benzoazepine and/or salt thereof (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50 wt.% or greater and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70μm, and a 90% cumulative particle diameter of 100 to 200μm.本發明提供一種新穎之藥學固體製劑,其具有較佳之崩解性質及優異安定性,導致經胃腸道之活性成份之足夠吸收性。本發明之藥學固體製劑包含:(a)7-氯-5-羥基-1-[2-甲基-4-(2-甲基苯甲醯基胺基)苯甲醯基]-2,3,4,5-四氫-1H-苯并氮呯及/或其鹽;(b)含有50重量%或更大之量之羥基丙氧基之羥基丙基纖維素;及(c)至少一選自羧甲基纖維素、羧甲基澱粉鈉、交聯聚維酮,及具30至70μm之平均顆粒直徑及100至200μm之90%累積顆粒直徑之低取代之羥基丙基纖維素所組成族群之成員。
